Abstracts tagged "Systemic sclerosis"

Abstract Number: 0676 • ACR Convergence 2025
Engineered glove for the objective assessment of hand dexterity in patients with systemic sclerosis: correlations with clinical features, nailfold videocapillaroscopy, and high frequency skin ultrasonography
Alberto Sulli¹, Elvis Hysa², Paolo Clini³, Emanuele Gotelli⁴, Tamara Vojinovic⁵, Carmen Pizzorni¹, Ali Jaffal³, Sabrina Paolino¹, Rosanna Campitiello³, Vanessa Smith⁶ and Maurizio Cutolo³, ¹University of Genoa, Genova, Italy, ²University of Genoa, Genoa, Italy, ³University of Genova, Genova, Italy, ⁴University of Genoa, Genoa, Liguria, Italy, ⁵University of Genoa, Genova, ⁶Ghent University Hospital, Gent, Belgium
Background/Purpose: Hand disability is a major feature of systemic sclerosis (SSc), driven by skin thickening and joint contractures, with significant impact on quality of life.…
Abstract Number: 0843 • ACR Convergence 2025
Efficacy and Safety of BMS-986353, a CD19-Directed Chimeric Antigen Receptor T Cell Therapy Manufactured Using a Next-Generation Process: Updated Data From a Phase 1 Trial in Patients With Systemic Sclerosis
Dinesh Khanna¹, David Korman², Elana Bernstein³, Neil Kramer⁴, Vikas Majithia⁵, Philip J. Mease⁶, Georg Schett⁷, Jacques Azzi⁸, Richard Nash⁹, Ran Reshef³, Mohammad Cherry¹⁰, Ernesto Ayala⁵, Matthew Schwede¹¹, Monalisa Ghosh¹², Fabian Müller¹³, Alisha Desai¹⁴, San-San Ou¹⁵, Sharmila Das¹⁴, Jerill Thorpe¹⁶, Melissa Harnois¹⁴, Alexis Melton¹⁶, Ashley Koegel¹⁶ and Margrit Wiesendanger⁸, ¹University of Michigan, Ann Arbor, MI, ²Mountain Rheumatology, Denver, CO, ³Columbia University Irving Medical Center, New York, NY, ⁴Overlook Medical Center; Atlantic Medical Group, Atlantic Health System, Summit, NJ, ⁵Mayo Clinic Hospital, Jacksonville, FL, ⁶Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ⁷Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ⁸Icahn School of Medicine at Mount Sinai, New York, NY, ⁹Health One Cares, Denver, CO, ¹⁰Atlantic Health System, Morristown, NJ, ¹¹Swedish Cancer Institute, Seattle, WA, ¹²C. S. Mott Children's Hospital University of Michigan Health, Ann Arbor, MI, ¹³University Hospital of Erlangen, Erlangen, Germany, ¹⁴Bristol Myers Squibb, Princeton, NJ, ¹⁵Bristol Myers Squibb, Seattle, WA, ¹⁶Bristol Myers Squibb, Princeton
Background/Purpose: BMS-986353 (CC-97540) is an investigational CD19-directed T-cell therapy expressing the chimeric antigen receptor (CAR) used in globally-approved lisocabtagene maraleucel; it is manufactured via the…
Abstract Number: 2656 • ACR Convergence 2025
Long-term effect of selexipag in systemic sclerosis-associated digital ulcers: a case control, multicentre, observational study
Claudia Iannone¹, Marco Di Battista², Maria Rosa Pellico³, ilaria Magi⁴, Antonina Minniti⁵, Giuseppe Armentaro⁴, Silvia Cavalli⁴, Manuel Sette⁴, Laura Giudice⁴, Cristina Bochicchio⁴, Alessandra Della Rossa⁶, Antonio Gaetano Tavoni⁷, Fabio Cacciapaglia⁸, Stefano Stano⁹, Martina Orlandi¹⁰, Dilia Giuggioli¹¹, Marta Mosca¹², Roberto Caporali¹³ and Nicoletta Del pAPA³, ¹University of Milan, Gaetano Pini CTO, Milano, Milan, Italy, ²Rheumatology Unit, University of Pisa, Pisa, Italy, ³ASST Pini-CTO, Clinical Rheumatology Unit, Milano, Italy, ⁴ASST Pini-CTO, Clinical Rheumatology Unit, Milan, Italy, ⁵ASST Gaetano Pini, milano, Milan, Italy, ⁶Rheumatology Unit, University of Pisa, Milan, Italy, ⁷Clinical Immunology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Milan, Italy, ⁸Rheumatology Unit DiMePRe-J, University and AOU Policlinico of Bari & Department of Medicine LUM "G. De Gegnnaro" University, Casamassima (Bari) - Italy, Bari, Italy, ⁹⁶. Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari, Bari, Italy, ¹⁰Rheumatology Unit, Department of Medical and Surgical Sciences for Children and Adults, University Hospital of Modena and Reggio Emilia School of Medicine, Italy., modena, Italy, ¹¹Scleroderma Unit, Rheumatology Unit, University Hospital of Modena and Reggio Emilia, Modena, Italy, Modena, Italy, ¹²University of Pisa, Pisa, Pisa, Italy, ¹³University of Milan and ASST Gaetano Pini-CTO, Milano, Italy
Background/Purpose: Digital ulcers (DUs) affect approximately 50% of SSc patients, causing significant pain and disability. Current management involves both systemic and local therapies. However, the…
Abstract Number: 2484 • ACR Convergence 2025
Phenotype of systemic sclerosis patients with positive anti–NOR-90 antibodies
Javier Narváez¹, Santos Castañeda², Montserrat Roig Kim³, Martí Aguilar-Coll⁴, Laia De Daniel Bisbe³, Marina Dueñas⁵, Cristina Valero⁶, Francisco Morandeira⁷, Miguel A. González-Gay⁸ and Joan Miquel Nolla³, ¹Hospital Universitario de Bellvitge, Barcelona, Spain, ²Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, ³Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain, ⁴Department of Rheumatology. Hospital Universitario de Bellvitge, Barcelona, Spain, ⁵Department of Rheumatology.Hospital Universitario de la Princesa, Madrid, Spain, ⁶Hospital de la Princesa, Madrid, Spain, ⁷Department of Immunology. Hospital Universitario de Bellvitge, Barcelona, Spain, ⁸Department of Rheumatology and Joint and Bone Research Unit, Hospital Universitario Fundación Jiménez Díaz, and Instituto de Investigación Sanitaria-Fundación Jiménez Díaz, Madrid, Spain, and Medicine and Psychiatry Department, University of Cantabria, Santander, Spain
Background/Purpose: To analyze the clinical associations of anti-Nucleolar Organizer Region 90 antibodies (NOR90) antibodies in patients with systemic sclerosis (SSc)Methods: Cross-sectional study of NOR90-positive SSc…
Abstract Number: 1873 • ACR Convergence 2025
TGF-β-Driven Mitochondrial Stress Activates cGAS-STING Signalling via Impaired Mitophagy in Systemic Sclerosis Endothelial Cells
Stefano Di Donato¹, Ceclie Bordes², Claude Lalou², agathe Depaire², John Tchen², Charlene Lhuissier², damien Brisou², Vanja Sisirak², Johan Garaude², Christopher Wasson³, Rebecca Ross⁴, Francesco Del Galdo³ and Marie-Elise Truchetet⁵, ¹University of Leeds, Canosa Sannita, Chieti, Italy, ²University of Bordeaux, Bordeaux, France, ³University of Leeds, Leeds, United Kingdom, ⁴Medicine and Health, University of Leeds, Leeds, United Kingdom, ⁵Bordeaux University Hospital, Bordeaux, France
Background/Purpose: Emerging evidence implicates mitochondrial dysfunction as a contributor to tissue fibrosis in systemic sclerosis (SSc) (1). Endothelial cells, which are a key player in…
Abstract Number: 1583 • ACR Convergence 2025
Epidemiology, Outcome and Expenditures of Hospitalized Patients with Systemic Sclerosis: National Inpatient Sample 2021
Patompong Ungprasert¹ and Paul Kroner², ¹Cleveland Clinic, Cleveland, OH, Cleveland Heights, OH, ²Riverside Health System, Newport News, VA
Background/Purpose: The inpatient epidemiology, morbidity, mortality, and healthcare expenditures of patients with systemic sclerosis (SSc) are not well-characterized. This study aims to utilize a nationwide…
Abstract Number: 1555 • ACR Convergence 2025
Prevalence of Organ Involvement and Baseline Predictors of Disease Progression in Patients with Limited Cutaneous Systemic Sclerosis: Insights from the CONQUER Database
Alain Lescoat¹, Virginia Steen², Monica Harding³, John VanBuren³, Brian Skaug⁴, Shervin Assassi⁵, Maureen Mayes⁶, Zsuzsanna McMahan⁷, Elana Bernstein⁸, Flavia Castelino⁹, Lorinda Chung¹⁰, Luke Evnin¹¹, Tracy Frech¹², Jessica Gordon¹³, Faye Hant¹⁴, Laura Hummers¹⁵, Kimberly Lakin¹³, Dorota Lebiedz-Odrobina³, Yiming Luo¹⁶, Ashima Makol¹⁷, Jerry Molitor¹⁸, Duncan Moore¹⁹, Carrie Richardson¹⁹, Nora Sandorfi²⁰, Ami Shah¹⁵, Ankoor Shah²¹, Elizabeth Volkmann²², Carleigh Zahn²³ and Dinesh Khanna²⁴, ¹CHU Rennes - University Rennes, Rennes, France, ²Georgetown University School of Medicine, Washington, DC, ³University of Utah, Salt Lake City, UT, ⁴UTHealth Houston Division of Rheumatology, Houston, TX, ⁵Division of Rheumatology, UTHealth Houston, Houston, Texas, USA, Houston, TX, ⁶UT Health Houston Division of Rheumatology, Houston, TX, ⁷UT Health Houston, Houston, TX, ⁸Columbia University Irving Medical Center, New York, NY, ⁹Massachusetts General Hospital, Boston, MA, ¹⁰Stanford University, Stanford, CA, ¹¹Scleroderma Research Foundation, San Francisco, CA, ¹²Vanderbilt University Medical Center, Nashville, TN, ¹³Hospital for Special Surgery, New York, NY, ¹⁴Medical University of South Carolina, Charleston, SC, ¹⁵Johns Hopkins Rheumatology, Baltimore, MD, ¹⁶Columbia University Irving Medical Center, New York, ¹⁷Mayo Clinic, Rochester, MN, ¹⁸University of Minnesota, Minneapolis, MN, ¹⁹Northwestern University, Chicago, ²⁰University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, ²¹Duke University, Durham, NC, ²²Division of Rheumatology, Department of Medicine, University of California, David Geffen School of Medicine, Los Angeles, CA, USA, Los Angeles, CA, ²³University of Michigan, Ann Arbor, ²⁴University of Michigan, Ann Arbor, MI
Background/Purpose: Systemic sclerosis (SSc) is characterized by a wide range of clinical manifestations and available interventions still lack overall efficacy. Limited cutaneous SSc (lcSSc) and…
Abstract Number: 0971 • ACR Convergence 2025
Unraveling the role of the hippo pathway in systemic sclerosis: A focus on TEADs and VGLL3
Neha Khanna¹, Alyssa Rosek¹, Alexander Cai¹, Olesya Plazyo², Johann Gudjonsson², Dinesh Khanna² and Pei-Suen Tsou², ¹Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA, Ann Arbor, ²University of Michigan, Ann Arbor, MI
Background/Purpose: Systemic sclerosis (SSc) is a chronic autoimmune disorder characterized by excessive collagen production, leading to the thickening and hardening of skin and internal organs.…
Abstract Number: 0704 • ACR Convergence 2025
Human Pharmacokinetics of Inhaled Liposomal Iloprost Support a Dosing Regimen for Treating Systemic Sclerosis- Related Digital Ulcer
Pei Kan, Ko-Chieh Chen and Shin-Shin Chuang, Pharmosa Biopharm Inc, Taipei, Taiwan (Republic of China)
Background/Purpose: Iloprost is recommended and widely used in Europe for treating systemic sclerosis (SSc)-related Raynaud Phenomena (RP) and Digital Ulcer (DU). EULAR recommendation suggests continuous…
Abstract Number: 0675 • ACR Convergence 2025
Neutrophil-to-Lymphocyte Ratio as a biomarker for disease onset and a predictor for mortality in Systemic Sclerosis – real-world data from a large healthcare provider in Israel.
Shiri Keret¹, Shlomit Yaari², gleb Slobodin³ and doron Rimar³, ¹Bnai Zion Medical Center, Atlit, Israel, ²Maccabi Healthcare Services, HaMered ²⁷, Tel Aviv, ⁶⁸¹²⁵, Israel., Tel Aviv, Israel, ³Bnai Zion Medical Center Faculty of Medicine, Technion Israel institute of technology, Haifa, Israel
Background/Purpose: Elevated neutrophil-to-lymphocyte ratio (NLR) in systemic sclerosis (SSc) has been demonstrated to predict worsening skin and lung involvement, and a cutoff of 2.95 was…
Abstract Number: 0810 • ACR Convergence 2025
Spatial Transcriptomic-based Phenotyping of the Fibroblast Niches in Systemic Sclerosis-associated Primary Heart Involvement
Alexandru Micu¹, Alexandru-Emil Matei², Yi-Nan Li³, Ann-Christin Pecher⁴, Tim Filla⁵, Jörg Henes⁶, Markus Eckstein⁷, Karin Klingel⁸, Jörg Distler⁹ and Andrea-Hermina Györfi¹⁰, ¹Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University, Düsseldorf, Germany, ²Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, and Fraunhofer Cluster of Excellence for Immune Mediated Diseases CIMD, Frankfurt am Main, Germany, Düsseldorf, Germany, ³University Hospital of Düsseldorf, Düsseldorf, Germany, ⁴Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology, and Rheumatology, University Hospital Tübingen, Tübingen, Germany, ⁵Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University., Düsseldorf, Germany, ⁶Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology, and Rheumatology, University Hospital Tübingen, Tuebingen, Germany, ⁷Institute of Pathology and Comprehensive Cancer Center EMN, Friedrich-Alexander- Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ⁸Cardiopathology, Institute for Pathology, Eberhard-Karls-Universität Tübingen, Tübingen, Germany, ⁹University Hospital Duesseldorf and HHU, Duesseldorf, Germany, ¹⁰Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University., Düsseldorf, Germany
Background/Purpose: Systemic sclerosis (SSc)-associated primary heart involvement (SSc-pHI) is one of the leading causes of mortality in SSc, yet its underlying cellular and molecular pathomechanisms…
Abstract Number: 2652 • ACR Convergence 2025
Anti-mitochondrial antibodies in systemic sclerosis target enteric neurons and are associated with GI dysmotility
Zsuzsanna McMahan¹, Srinivas Puttapaka², Livia Casciola-Rosen³, Timothy Kaniecki³, Laura Gutierrez³, Su Hong MIng², Philippa Seika² and Subhash Kulkarni⁴, ¹UT Health Houston, Houston, TX, ²BIDMC/Harvard, Boston, MA, ³Johns Hopkins University, Baltimore, MD, ⁴BIDMC, Boston, MA
Background/Purpose: Most patients with systemic sclerosis (SSc) experience gastrointestinal (GI) dysmotility. The enteric nervous system (ENS) regulates GI motility, and its dysfunction causes dysmotility. A…
Abstract Number: 2483 • ACR Convergence 2025
Is There a Seasonal Variation in Raynaud’s Phenomenon Severity in Patients with Systemic Sclerosis?
Gulsen Ozen¹, Lan Yu², Maureen Lauffoon², John Pauling³ and Robyn Domsic², ¹University of Iowa Carver College of Medicine, Coralville, IA, ²University of Pittsburgh, Pittsburgh, PA, ³North Bristol NHS Trust, Bristol, United Kingdom
Background/Purpose: Raynaud’s phenomenon (RP) is the most common manifestation of systemic sclerosis (SSc) leading to substantial pain and impaired hand function. Establishing treatment efficacy for…
Abstract Number: 1871 • ACR Convergence 2025
Examining the impact of ETV2 on altered endothelial phenotype in systemic sclerosis
Elio Carmona¹, Alyssa Rosek², Neha Khanna², Dinesh Khanna³, Amr Sawalha⁴ and Pei-Suen Tsou³, ¹Division of Pediatric Rheumatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA, Pittsburgh, ²Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA, Ann Arbor, ³University of Michigan, Ann Arbor, MI, ⁴University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Our prior research demonstrated that epigenetic modifications are central to the pathogenesis of scleroderma (SSc)1. Using ATAC-seq, we found that chromatin accessibility was significantly…
Abstract Number: 1582 • ACR Convergence 2025
Risk factors for incident digital ischemic complications in systemic sclerosis in the Collaborative National Quality and Efficacy Registry (CONQUER)
Marissa Savoie¹, Monica Harding², John VanBuren², Shervin Assassi³, Elana Bernstein⁴, Lorinda Chung⁵, Luke Evnin⁶, Tracy Frech⁷, Jessica Gordon¹, Faye Hant⁸, Laura Hummers⁹, Dinesh Khanna¹⁰, Kimberly Lakin¹, Dorota Lebiedz-Odrobina², Yiming Luo⁴, Ashima Makol¹¹, Maureen Mayes¹², Zsuzsanna McMahan¹³, Jerry Molitor¹⁴, Duncan Moore¹⁵, Carrie Richardson¹⁶, Nora Sandorfi¹⁷, Ami Shah⁹, Ankoor Shah¹⁸, Brian Skaug¹⁹, Virginia Steen²⁰, Elizabeth Volkmann²¹, Carleigh Zahn¹⁰ and Flavia Castelino²², ¹Hospital for Special Surgery, New York, NY, ²University of Utah, Salt Lake City, UT, ³Division of Rheumatology, UTHealth Houston, Houston, Texas, USA, Houston, TX, ⁴Columbia University, New York, NY, ⁵Stanford University, Stanford, CA, ⁶Scleroderma Research Foundation, Brisbane, CA, ⁷Vanderbilt University Medical Center, Nashville, TN, ⁸Medical University of South Carolina, Charleston, SC, ⁹Johns Hopkins Rheumatology, Baltimore, MD, ¹⁰University of Michigan, Ann Arbor, MI, ¹¹Mayo Clinic, Rochester, MN, ¹²UT Health Houston Division of Rheumatology, Houston, TX, ¹³UT Health Houston, Houston, TX, ¹⁴University of Minnesota, Minneapolis, MN, ¹⁵Northwestern Memorial Hospital, Chicago, IL, ¹⁶Northwestern University, Chicago, IL, ¹⁷University of Pennsylvania, Philadelphia, PA, ¹⁸Duke University, Durham, NC, ¹⁹UTHealth Houston Division of Rheumatology, Houston, TX, ²⁰Georgetown University School of Medicine, Washington, DC, ²¹Division of Rheumatology, Department of Medicine, University of California, David Geffen School of Medicine, Los Angeles, CA, USA, Los Angeles, CA, ²²Massachusetts General Hospital, Boston, MA
Background/Purpose: There have not been large US-based studies of digital pitting scars (DPS) and digital ischemic ulcers (DIU) in systemic sclerosis. Utilizing the Collaborative National…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].